N-Terminal Plasmodium vivax Merozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine
Figure 2
Comparison of total IgG and IgG3 levels against ICB2-5. Comparison of antibodies of individuals from study [42] separated according to subjects who have had acute malaria in last 90 days and symptomless P. vivax-infected individuals. Median of antibodies against ICB2-5 was compared by Kruskal Wallis. (a) Total IgG; (b) IgG3.
